CORAL: Classification model for predictions of anti-sarcoma activity

Current Topics in Medicinal Chemistry

Volumn 12, Issue 24, 2012, Pages 2741-2744

  Toropov, A A ^a   Toropova, A P ^a   Benfenati, E ^a   Gini, G ^b   Leszczynska, D ^c   Leszczynski, J ^d  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c Jackson State University   (United States)

^d JACKSON STATE UNIVERSITY   (United States)

Author keywords

Anti sarcoma activity; Classification model; CORAL software; Monte Carlo method; QSAR

Indexed keywords

ANTINEOPLASTIC ACTIVITY; ANTISARCOMA ACTIVITY; ARTICLE; COMPUTER PROGRAM; CORAL SOFTWARE; DRUG CLASSIFICATION; EXPERIMENTAL DESIGN; MEASUREMENT ACTIVITY; MONTE CARLO METHOD; PROCESS OPTIMIZATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; CHEMISTRY; CLASSIFICATION; DRUG DEVELOPMENT; HUMAN; MOLECULAR LIBRARY; SARCOMA; SENSITIVITY AND SPECIFICITY; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENT;

ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; HUMANS; MONTE CARLO METHOD; SARCOMA; SENSITIVITY AND SPECIFICITY; SMALL MOLECULE LIBRARIES; SOFTWARE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84883736269     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026611212240004     Document Type: Article

References (51)

1. Speck-Planche A.; Kleandrova V.V.; Luan F.; Cordeiro M.N.D.S. Fragment-based QSAR model toward the selection of versatileanti-sarcoma leads. Eur. J. Med. Chem., 2011, 46, 5910-5916.
2. ahin K.; Saripinar E.; Yanmaz E.; Geçen, N. Quantitative bioac-tivity prediction and pharmacophore identification for benzotriaz-ine derivatives using the electron conformational-genetic algorithmin QSAR. SAR QSAR Environ. Res. 2011, 22, 217-238.
3. Liu J.; Zhao M.; Qian K.; Zhang X.; Lee K.-H.; Wu, J.; Liu, Y.-N.; Peng, S. Benzyl 1,2,3,5,11,11a-hexahydro-3,3-dimethyl-1-oxo-6H-imidazo [3’,4’:1,2]pyridine [3,4-b]indole-2-substituted acetates: One-pot-preparation, anti-tumor activity, docking toward DNA and 3DQSAR analysis. Bioorg. Med. Chem. 2010, 18, 1910-1917.
4. Wu J.; Zhao M.; Qian K.; Lee K.-H.; Morris-Natschke S.; Peng, S. Novel N-(3-carboxyl-9-benzyl- -carboline-1-yl)ethylamino acids:Synthesis, anti-tumor evaluation, intercalating determination, 3DQSAR analysis and docking investigation. Eur. J. Med. Chem.,2009, 44, 4153-4161.
5. Sutherland T.E.; Anderson R.L.; Hughes R.A.; Altmann E.; Schu-liga M.; Ziogas J.; Stewart A.G. 2-Methoxyestradiol - a uniqueblend of activities generating a new class of anti-tumour/anti-inflammatory agents. Drug Discov. Today, 2007, 12, 577-584.
6. Chung Y.; Shin Y.-K.; Zhan C.-G.; Lee S.; Cho H. Synthesis andevaluation of antitumor activity of 2- and 6-[(1,3-benzothiazol-2-yl)aminomethyl]-5,8-dimethoxy-1,4- naphthoquinone derivatives. Arch. Pharm. Res., 2004, 27, 893-900.
7. Ferreira M.M.C. Multivariate QSAR. J. Braz. Chem. Soc., 2002,13, 742-753.
8. Mazerska Z.; Ledochowski A. QSAR of acridines. I. Search forantitumour derivatives of 1-nitro-9(3-aminopropylamino)acridine. Eur. J. Med. Chem. 1984, 19, 199-204.
9. Niculescu-Duvaz I.; Stihi G.; Craescu T.; Simon, Z. Potential anti-cancer agents. XX. 2. Quantitative structure-activity relationships(QSAR) in aromatic nitrogen mustards area. Neoplasma, 1980, 27,271-278.
10. Wu R.S.; Wolpert-DeFilippes M.K.; Quinn, F.R. Quantitativestructure-activity correlations of rifamycins as inhibitors of viralRNA-directed DNA polymerase and mammalian and DNA po-lymerases. J. Med. Chem., 1980, 23, 256-261.
11. Estrada E.; Peña, A.; García-Domenech R. Designing seda-tive/hypnotic compounds from a novel substructural graph-theoretical approach. J. Comput-Aid. Mol. Des., 1998, 12, 583-595.
12. Estrada E.; Uriarte E.; Montero A.; Teijeira M.; Santana L.; De Clercq E. A novel approach for the virtual screening and rationaldesign of anticancer compounds. J. Med. Chem., 2000, 43, 1975-1985.
13. Gálvez J.; Garcia-Domenech R.; De Julián-Ortiz V.; Soler, R. Topological approach to analgesia. J. Chem. Inf. Comput. Sci.,1994, 34, 1198-1203.
14. García-Domenech R.; López-Peña W.; Sanchez-Perdomo Y.; Sanders J.R.; Sierra-Araujo M.M.; Zapata C.; Gálvez, J. Application of molecular topology to the prediction of the antimalarial ac-tivity of a group of uracil-based acyclic and deoxyuridine compounds. Int. J. Pharm., 2008, 363, 78-84.
15. González Díaz H.; Olazabal E.; Castañedo N.; Hernández SánchezI.; Morales A.; Serrano H.S.; González J.; Ramos de Armas R. Markovian chemicals "in silico" design (MARCH-INSIDE), apromising approach for computer aided molecular disign II: Ex-perimental and theoretical assessment of a novel method for virtualscreening of fasciolicides. J. Mol. Model., 2002, 8, 237-245.
16. González-Díaz H.; Olazábal E.; Santana L.; Uriarte E.; González-Díaz Y.; Castañedo N. QSAR study of anticoccidial activity for di-verse chemical compounds: Prediction and experimental assay oftrans-2-(2-nitrovinyl)furan. Bioorg. Med. Chem., 2007, 15, 962-968.
17. Marrero-Ponce Y.; Khan M.T.H.; Casañola-Martín G.M.; Ather A.; Sultankhodzhaev M.N.; GarcíDomenech R.; Torrens F.; Rotondo R. Bond-based 2D TOMOCOMD-CARDD approach for drug dis-covery: Aiding decision-making in 'in silico' selection of new leadtyrosinase inhibitors. J. Comput-Aid. Mol. Des., 2007, 21, 167-188.
18. Marrero-Ponce Y.; Meneses-Marcel A.; Rivera-Borroto O.M.; García-Domenech R.; Julián-Ortiz J.V.; Montero A.; Escario J.A.; Barrio A.G.; Pereira D.M.; Nogal J.J.; Grau R.; Torrens F.; Vogel C.; Arán V.J. Bond-based linear indices in QSAR: Computationaldiscovery of novel anti-trichomonal compounds. J. Comput-Aid.Mol. Des., 2008, 22, 523-540.
19. Bagchi M.C.; Mills D.; Basak S.C. Quantitative structure-activityrelationship (QSAR) studies of quinolone antibacterials against M.fortuitum and M. smegmatis using theoretical molecular descrip-tors. J. Mol. Model., 2007, 13, 111-120.
20. Morales Helguera A.; Cabrera Pérez M.A.; Pérez González M.; Ruiz Molina R.; González Díaz H. A topological substructural approach applied to the computational prediction of rodent carcino-genicity. Bioorg. Med. Chem., 2005, 13, 2477-2488.
21. Toropov A.A.; Toropova A.P.; Benfenati E.; Gini G.; Leszczynska D.; Leszczynski, J. SMILES-based QSAR approaches for carcino-genicity and anticancer activity: Comparison of correlation weightsfor identical SMILES attributes. Anti-Cancer Agents Med. Chem.,2011, 11, 974-982.
22. Mullen L.M.A.; Duchowicz P.R.; Castro, E.A. QSAR treatment ona new class of triphenylmethyl-containing compounds as potentanticancer agents. Chemometr. Intel. Lab. Syst., 2011, 107, 269-275.
23. Benfenati, E.; Toropov, A.A.; Toropova, A.P.; Manganaro, A.; Gonela Diaza, R. CORAL for Windows,http://www.insilico.eu/coral, IRFMN, Milano, 2012
24. Estrada, E.; Gutiérrez, Y. MODESLAB, v1.5; Santiago de Compos-tela, 2002-2004.
25. Estrada, E.; Uriarte, E.; Montero, A.; Teijeira, M.; Santana, L.; De Clercq, E. A novel approach for the virtual screening and rationaldesign of anticancer compounds. J. Med. Chem., 2000, 43, 1975-1985.
26. Todeschini, R.; Consonni, V.; Mauri, A.; Pavan, M. DRAGON forWindows (Software for Molecular Descriptor Calculations), v5.3;Milano Chemometrics and QSAR Research Group: Milano, 2005
27. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in multi-target drug discovery for anti-cancertherapy: in silico design of potent and versatile anti-brain tumoragents. Anticancer Agents Med. Chem., 2012, 12, 678-685.
28. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Chemoinformatics in anti-cancer chemotherapy: multi-targetQSAR model for the in silico discovery of anti-breast canceragents. Eur. J. Pharm. Sci., 2012, 47, 273-279.
29. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Rational drug design for anti-cancer chemotherapy: multi-targetQSAR models for the in silico discovery of anti-colorectal canceragents. Bioorg. Med. Chem., 2012, 20, 4848-4855.
30. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Multi-target drug discovery in anti-cancer therapy: fragment-basedapproach toward the design of potent and versatile anti-prostatecancer agents. Bioorg. Med. Chem., 2011, 19, 6239-6244.
31. Speck-Planche, A.; Kleandrova, V.V.; Luan, F.; Cordeiro, M.N. Fragment-based QSAR model toward the selection of versatileanti-sarcoma leads. Eur. J. Med. Chem., 2011, 46, 5910-5916.
32. Ferino, G.; Gonzalez-Diaz, H.; Delogu, G.; Podda, G.; Uriarte, E. Using spectral moments of spiral networks based on PSA/massspectra outcomes to derive quantitative proteome-disease relation-ships (QPDRs) and predicting prostate cancer. Biochem. Biophys.Res. Commun., 2008, 372, 320-325.
33. Gonzalez-Diaz, H.; Bonet, I.; Teran, C.; De Clercq, E.; Bello, R.; Garcia, M.M.; Santana, L.; Uriarte, E. ANN-QSAR model for se-lection of anticancer leads from structurally heterogeneous series ofcompounds. Eur. J. Med. Chem., 2007, 42, 580-585.
34. Gonzalez-Diaz, H.; Vina, D.; Santana, L.; de Clercq, E.; Uriarte, E. Stochastic entropy QSAR for the in silico discovery of anticancercompounds: prediction, synthesis, and in vitro assay of new purinecarbanucleosides. Bioorg. Med. Chem., 2006, 14, 1095-1107.
35. Marzaro, G.; Chilin, A.; Guiotto, A.; Uriarte, E.; Brun, P.; Casta-gliuolo, I.; Tonus, F.; Gonzalez-Diaz, H. Using the TOPS-MODEapproach to fit multi-target QSAR models for tyrosine kinases in-hibitors. Eur. J. Med. Chem., 2011, 46, 2185-2192.
36. Munteanu, C.R.; Magalhaes, A.L.; Uriarte, E.; Gonzalez-Diaz, H. Multi-target QPDR classification model for human breast and co-lon cancer-related proteins using star graph topological indices. J.Theor. Biol., 2009, 257, 303-311.
37. Vilar, S.; Gonzalez-Diaz, H.; Santana, L.; Uriarte, E. A network-QSAR model for prediction of genetic-component biomarkers inhuman colorectal cancer. J. Theor. Biol., 2009, 261, 449-458.
38. Marrero-Ponce, Y.; Romero, V. TOMOCOMD (TOpological MO-lecular COMputer Design) forWindows, v1.0; Villa Clara, 2002.
39. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Khan, M.T.; Khan, S.B.; Torrens, F.; Perez-Jimenez, F.; Rescigno, A.; Abad, C. Bond-based 2D quadratic fingerprints in QSAR studies: virtual and in vi-tro tyrosinase inhibitory activity elucidation. Chem Biol Drug Des,2010, 76, 538-545.
40. Le-Thi-Thu, H.; Casanola-Martin, G.M.; Marrero-Ponce, Y.; Res-cigno, A.; Saso, L.; Parmar, V.S.; Torrens, F.; Abad, C. Novelcoumarin-based tyrosinase inhibitors discovered by OECD princi-ples-validated QSAR approach from an enlarged, balanced database. Mol. Divers., 2011, 15, 507-520.
41. Casanola-Martin, G.M.; Marrero-Ponce, Y.; Tareq Hassan Khan, M.; Torrens, F.; Perez-Gimenez, F.; Rescigno, A. Atom- and bond-based 2D TOMOCOMD-CARDD approach and ligand-based vir-tual screening for the drug discovery of new tyrosinase inhibitors.J. Biomol. Screen., 2008, 13, 1014-1024.
42. Marrero-Ponce, Y.; Khan, M.T.; Casanola Martin, G.M.; Ather, A.; Sultankhodzhaev, M.N.; Torrens, F.; Rotondo, R. Prediction of ty-rosinase inhibition activity using atom-based bilinear indices. ChemMedChem, 2007, 2, 449-478.
43. Marrero-Ponce, Y.; Khan, M.T.; Casanola-Martin, G.M.; Ather, A.; Sultankhodzhaev, M.N.; Garcia-Domenech, R.; Torrens, F.; Ro-tondo, R. Bond-based 2D TOMOCOMD-CARDD approach fordrug discovery: aiding decision-making in 'in silico' selection of new lead tyrosinase inhibitors. J. Comput. Aided Mol. Des., 2007,21, 167-188.
44. Lahat, G.; Lazar, A.; Lev, D. Sarcoma epidemiology and etiology:potential environmental and genetic factors. Surg Clin North Am,2008, 88, 451-481.
45. Toropova A.P.; Toropov A.A.; Benfenati E.; Gini, G. QSAR modelling toxicity toward rats of inorganic substances by means ofCORAL. Cent. Eur. J. Chem., 2011, 9, 75-85.
46. Toropova A.P.; Toropov A.A.; Diaza R.G.; Benfenati E.; Gini, G. Analysis of the co-evolutions of correlations as a tool for QSAR-modeling of carcinogenicity: An unexpected good prediction basedon a model that seems untrustworthy. Cent. Eur. J. Chem. 2011, 9,165-174.
47. Toropova A.P.; Toropov A.A.; Benfenati E.; Gini, G. Co-evolutions of correlations for QSAR of toxicity of organometallicand inorganic substances: An unexpected good prediction based ona model that seems untrustworthy. Chemometr. Intel. Lab. Syst.,2011, 105, 215-219.
48. Toropov A.A.; Toropova A.P.; Lombardo A.; Roncaglioni A.; Benfenati E.; Gini, G. CORAL: Building up the model for biocon-centration factor and defining it's applicability domain. Eur. J.Med. Chem., 2011, 46, 1400-1403.
49. Toropova A.P.; Toropov A.A.; Benfenati E.; Gini G.; Leszczynska D.; Leszczynski, J. CORAL: QSPR models for solubility of [C 60]and [C 70] fullerene derivatives. Mol. Divers. 2011, 15, 249-256.
50. Ojha P.K.; Mitra I.; Das R.N.; Roy, K. Further exploring rm 2metrics for validation of QSPR models. Chemometr. Intel. Lab.Syst., 2011, 107, 194-205
51. Kar S.; Roy, K. Development and validation of a robust QSARmodel for prediction of carcinogenicity of drugs. Indian J. Bio-chem. Biophys., 2011, 48, 111-122.